308 related articles for article (PubMed ID: 27750032)
1. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
[TBL] [Abstract][Full Text] [Related]
2. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
[TBL] [Abstract][Full Text] [Related]
3. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
[TBL] [Abstract][Full Text] [Related]
4. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
5. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
[TBL] [Abstract][Full Text] [Related]
6. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
7. Early Aβ reduction prevents progression of cerebral amyloid angiopathy.
Schelle J; Wegenast-Braun BM; Fritschi SK; Kaeser SA; Jährling N; Eicke D; Skodras A; Beschorner N; Obermueller U; Häsler LM; Wolfer DP; Mueggler T; Shimshek DR; Neumann U; Dodt HU; Staufenbiel M; Jucker M
Ann Neurol; 2019 Oct; 86(4):561-571. PubMed ID: 31359452
[TBL] [Abstract][Full Text] [Related]
8. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.
Shimshek DR; Jacobson LH; Kolly C; Zamurovic N; Balavenkatraman KK; Morawiec L; Kreutzer R; Schelle J; Jucker M; Bertschi B; Theil D; Heier A; Bigot K; Beltz K; Machauer R; Brzak I; Perrot L; Neumann U
Sci Rep; 2016 Feb; 6():21917. PubMed ID: 26912421
[TBL] [Abstract][Full Text] [Related]
10. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1.
Wang X; Wang Y; Hu JP; Yu S; Li BK; Cui Y; Ren L; Zhang LD
Mol Neurobiol; 2017 May; 54(4):2939-2949. PubMed ID: 27023226
[TBL] [Abstract][Full Text] [Related]
12. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease.
Liang B; Duan BY; Zhou XP; Gong JX; Luo ZG
J Biol Chem; 2010 Sep; 285(36):27737-44. PubMed ID: 20595388
[TBL] [Abstract][Full Text] [Related]
13. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
Eketjäll S; Janson J; Jeppsson F; Svanhagen A; Kolmodin K; Gustavsson S; Radesäter AC; Eliason K; Briem S; Appelkvist P; Niva C; Berg AL; Karlström S; Swahn BM; Fälting J
J Neurosci; 2013 Jun; 33(24):10075-84. PubMed ID: 23761903
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
[TBL] [Abstract][Full Text] [Related]
16. β-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau.
Tsolakidou A; Alexopoulos P; Guo LH; Grimmer T; Westerteicher C; Kratzer M; Jiang M; Bujo H; Roselli F; Leante MR; Livrea P; Kurz A; Perneczky R
Alzheimers Dement; 2013 Jul; 9(4):386-91. PubMed ID: 23127467
[TBL] [Abstract][Full Text] [Related]
17. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis.
Zhao J; Fu Y; Yasvoina M; Shao P; Hitt B; O'Connor T; Logan S; Maus E; Citron M; Berry R; Binder L; Vassar R
J Neurosci; 2007 Apr; 27(14):3639-49. PubMed ID: 17409228
[TBL] [Abstract][Full Text] [Related]
18. Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein.
Maia LF; Kaeser SA; Reichwald J; Hruscha M; Martus P; Staufenbiel M; Jucker M
Sci Transl Med; 2013 Jul; 5(194):194re2. PubMed ID: 23863834
[TBL] [Abstract][Full Text] [Related]
19. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
Sadleir KR; Eimer WA; Cole SL; Vassar R
Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
